- Home
- CMLS vs KPRX Comparison
CMLS vs KPRX Comparison
Compare CMLS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMLS
- KPRX
- Stock Information
- Founded
- CMLS 2002
- KPRX 1998
- Country
- CMLS United States
- KPRX United States
- Employees
- CMLS N/A
- KPRX N/A
- Industry
- CMLS Broadcasting
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CMLS Consumer Discretionary
- KPRX Health Care
- Exchange
- CMLS Nasdaq
- KPRX Nasdaq
- Market Cap
- CMLS 14.5M
- KPRX 9.8M
- IPO Year
- CMLS 1998
- KPRX N/A
- Fundamental
- Price
- CMLS $0.42
- KPRX $3.25
- Analyst Decision
- CMLS
- KPRX Strong Buy
- Analyst Count
- CMLS 0
- KPRX 1
- Target Price
- CMLS N/A
- KPRX $10.00
- AVG Volume (30 Days)
- CMLS 49.2K
- KPRX 17.1K
- Earning Date
- CMLS 05-02-2025
- KPRX 03-24-2025
- Dividend Yield
- CMLS N/A
- KPRX N/A
- EPS Growth
- CMLS N/A
- KPRX N/A
- EPS
- CMLS N/A
- KPRX 1.69
- Revenue
- CMLS $827,076,000.00
- KPRX $16,020,000.00
- Revenue This Year
- CMLS N/A
- KPRX N/A
- Revenue Next Year
- CMLS $0.79
- KPRX N/A
- P/E Ratio
- CMLS N/A
- KPRX $1.93
- Revenue Growth
- CMLS N/A
- KPRX N/A
- 52 Week Low
- CMLS $0.41
- KPRX $2.91
- 52 Week High
- CMLS $3.78
- KPRX $6.48
- Technical
- Relative Strength Index (RSI)
- CMLS 23.23
- KPRX 45.49
- Support Level
- CMLS $0.50
- KPRX $3.07
- Resistance Level
- CMLS $0.56
- KPRX $3.53
- Average True Range (ATR)
- CMLS 0.10
- KPRX 0.16
- MACD
- CMLS -0.04
- KPRX 0.00
- Stochastic Oscillator
- CMLS 1.68
- KPRX 54.91
About CMLS Cumulus Media Inc.
Cumulus Media Inc is an audio-first media company delivering content to over a quarter billion people every month wherever and whenever required. It is a radio broadcasting company combining high-quality local programming with iconic, nationally syndicated media, sports, and entertainment brands to deliver premium content choices to its customers and radio stations affiliated with Westwood One network and numerous digital channels. The company's revenue is derived mainly from the sale of local, regional, and national advertising which is broadcast on its radio stations.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.